Canada Is Losing Germany: What 2026 Export Data Says About EU-GMP

For most of the past decade, the story of Canadian medical cannabis in Europe was a story of dominance. Canadian licensed producers built the supply chains, held the certifications, and shipped the flower that stocked German pharmacies. In 2026, that story is changing. Germany is still the largest regulated medical cannabis market in the world, and it is still growing quickly, but the Canadian share of it is starting to slip while lower cost, newly certified origins move in.

This article is written for the person who feels that shift in the revenue line before they see it in a compliance report: the chief executive, the founder, the head of commercial. The headline is simple. The one structural advantage that still protects Canadian access to Germany and the wider European Union is regulatory, not agricultural. It is EU-GMP certification, backed by Good Agricultural and Collection Practice, or GACP. Producers who hold it keep their route to market. Producers who deferred it are the ones watching volume move to certified competitors.

Executive summary

What the 2026 export numbers actually show

In short: Germany's medical cannabis market is expanding, but Canada is supplying a shrinking slice of it. Germany's Federal Institute for Drugs and Medical Devices, BfArM, reports record import volumes through 2025 and into 2026, while trade reporting shows Canadian tonnage into Germany falling year over year as new suppliers, notably Thailand, scale quickly. The market is growing and Canada's position in it is not.

The scale of the German market is not in dispute. BfArM, which publishes quarterly import statistics, recorded roughly 201 tonnes of medical cannabis imported in 2025, a large increase over the prior year, and the first quarter of 2026 set a new quarterly record. Those figures come directly from a national regulator and are the most reliable data points available.

The competitive picture is where the caution lies. Trade and industry publications tracking German import data report that Canadian supply into Germany fell from roughly 62,000 kilograms in 2025 to roughly 49,000 kilograms across a comparable 2026 window, while Thai supply rose from about 1,000 kilograms to more than 20,000 kilograms over the same comparison. Canada remained the single largest supplier in early 2026, but its share has been trending down from the highs it held in 2024.

The German market in context

Why EU-GMP is the only structural barrier left

In short: price, climate and labour advantages can all be copied by another country, but a European quality standard cannot be skipped. To sell a cannabis medicine in Germany, the product must be cultivated under GACP, manufactured and tested under EU-GMP, and then released batch by batch by a Qualified Person inside the European Union. That chain of requirements is the moat. It is the one advantage a lower cost competitor cannot simply undercut.

Germany treats medical cannabis as a pharmaceutical. Under the German Medical Cannabis Act and the wider EU pharmaceutical framework, an importer must show that cultivation followed GACP and that production and quality control followed EU-GMP, and must hold the necessary import and manufacturing authorisations. The border is not a customs formality. It is a pharmaceutical quality gate.

The gate has a specific mechanism. Even a site with a valid EU-GMP certificate cannot place a batch on the EU market on its own. Every batch must be certified by a Qualified Person, a statutory role defined in Article 48 of Directive 2001/83/EC and governed by EudraLex Volume 4, Annex 16. For imported product, that certification happens only after the batch has physically arrived in the EU and been checked against the registered file. A producer without the certification chain behind it has no route through that gate, no matter how good or how inexpensive the flower is.

The two routes for a third country supplier

In short: a Canadian producer can reach the German market in one of two compliant ways. Either obtain EU-GMP certification for your own site through inspection by an EU member state authority, or route your product through an already licensed EU site that performs the EU-GMP steps and Qualified Person release for you. The first route protects your margin and your brand. The second protects your access but hands part of the value to someone else.

Member state authorities including BfArM, Infarmed and the Danish Medicines Agency have all conducted EU-GMP inspections of third country sites in Canada and elsewhere, so the first route is well established. The choice between the two is a commercial strategy question as much as a regulatory one, and it should be made deliberately rather than by default.

What certification actually takes

In short: EU-GMP certification is measured in quarters, not weeks, and in a documented quality system, not a single audit. The timeline depends on the gap between your current Good Production Practices baseline and the EU-GMP standard. A site already operating a mature quality system under Canadian licensing is far closer than one that treats documentation as an afterthought.

Rather than quote a single price or duration, which varies widely by facility, it is more useful to understand what drives them. The cost and the calendar are set by the size of the gap between where a site is today and where EU-GMP expects it to be. The main drivers include:

• The maturity of the pharmaceutical quality system, including change control, deviation management, CAPA and management review.
• The completeness and accuracy of the documentation set, from the site master file to individual batch records and standard operating procedures.
• Facility and equipment qualification, environmental monitoring, and a documented contamination control strategy aligned with EU-GMP Annex 1.
• Analytical method validation, stability data, and the strength of supplier and material controls.
• The availability of a Qualified Person arrangement and the readiness of the site to be inspected by an overseas authority.

Each of these is a project in its own right. This is why a realistic programme starts with an honest gap assessment against the EU-GMP standard, then closes the gaps in priority order. Our 2026 EU-GMP and GACP certification roadmap for the German market walks through the sequence, and our guide to how and why Canadian producers get EU-GMP certified covers the fundamentals. The Annex 1 contamination control strategy is one of the most common places a Canadian site discovers real work is required.

What happens to producers who stay uncertified

In short: uncertified producers do not lose Germany overnight. They lose it gradually, as certified competitors win the supply agreements, as pricing pressure from lower cost certified origins erodes their margin, and as the buyers who used to depend on them build relationships elsewhere. By the time the revenue decline is obvious, the certified competitor has already taken the shelf space.

There is a second, quieter risk. A shortcut sometimes described as GMP washing, where product is moved through a jurisdiction to acquire a compliance label it did not truly earn, is exactly the kind of practice regulators are tightening against. Germany's handling of the cannabis drying step is one example of a specific rule that catches producers who assumed a light touch would be enough. We cover that trap in detail in our article on GMP washing and Germany's drying rule. The direction of travel is toward more scrutiny, not less, which makes genuine certification the durable position.

Trade pressure is also arriving from more than one direction at once. Canadian producers are simultaneously managing an anti-dumping probe in Israel and the domestic inspection expectations visible in Health Canada's own cannabis inspection data. A firm that is strong on EU-GMP is better placed to absorb all of it, because the same quality system underpins every one of these markets.

EU-GMP readiness checklist

Use this as a first, honest self test before you commission a formal gap assessment. If you cannot answer yes with evidence to most of these, certification is a project you should scope now, not later.

• You have a documented pharmaceutical quality system with functioning change control, deviations, CAPA and management review.
• Your site master file is current and reflects what the facility actually does.
• Batch records are contemporaneous, complete and reconcile to inventory.
• Cultivation is documented under GACP, with a clear link from seed or clone to finished batch.
• You have a documented contamination control strategy aligned with EU-GMP Annex 1.
• Facilities, utilities and equipment are qualified, with current environmental monitoring data.
• Analytical methods are validated and stability data supports your claimed shelf life.
• Supplier and material controls are documented and evidence real oversight, not just a name on a list.
• You have identified a Qualified Person route for EU batch release.
• You have named an EU member state authority as your likely certifying inspectorate and understand its expectations.

Common mistakes that delay certification

In short: most certification delays are not caused by the facility. They are caused by the documentation and the quality system behind it. The physical plant is usually closer to ready than the paperwork that has to prove it.

• Treating EU-GMP as a facility upgrade rather than a quality system build. Inspectors read the records, not just the rooms.
• Starting without a gap assessment, so remediation is reactive and the timeline stretches.
• A contamination control strategy that exists on paper but is not connected to real monitoring data and real decisions.
• Batch records completed after the fact, which is a data integrity finding waiting to happen.
• Supplier qualification that names a supplier but cannot evidence oversight of it.
• Leaving the Qualified Person and member state inspectorate questions until the end, when they should shape the plan from the start.

Frequently asked questions

Do I need EU-GMP to export cannabis to Germany from Canada?

Yes, in practical terms. Germany treats medical cannabis as a pharmaceutical. The product must be cultivated under GACP and manufactured and tested under EU-GMP, and every batch must be released by an EU based Qualified Person. Either your own site holds EU-GMP certification, or you route the product through a licensed EU site that performs those steps for you.

Why are Canadian cannabis exports to Germany declining?

The German market is growing, but lower cost certified suppliers, notably Thailand, have scaled quickly and taken share. Canada remains a leading supplier, yet its slice of a rapidly expanding market is shrinking. The producers keeping their position are the ones with the certification and quality systems that buyers require.

How long does EU-GMP certification take?

It is measured in quarters, not weeks, and the honest answer depends on the gap between your current quality system and the EU-GMP standard. A site with a mature, well documented system may be inspection ready in a matter of months, while a site that needs to rebuild documentation, qualification and its contamination control strategy should plan for considerably longer.

Which authority certifies a Canadian site for EU-GMP?

An EU member state authority performs the inspection and issues the certificate. Authorities including Germany's BfArM, Portugal's Infarmed and Denmark's DKMA have inspected third country sites in Canada. The choice of inspectorate is part of your certification strategy and affects both timeline and expectations.

What is the difference between GACP and EU-GMP?

GACP, Good Agricultural and Collection Practice, governs cultivation and the early handling of the plant. EU-GMP governs manufacturing, testing and release of the finished medicinal product. Germany requires evidence of both. Our guide comparing EU-GMP and GPP explains how the standards relate and which one applies where.

Is certification worth it for a smaller producer?

That is a commercial calculation, and it starts with a scoped readiness assessment rather than a guess. Certification is the price of durable access to the highest value cannabis market in the world. For a producer whose strategy depends on Europe, the more expensive option is usually to wait, lose the shelf space, and try to win it back later.

How MFLRC can help

MFLRC helps Canadian cannabis producers turn EU-GMP from an anxiety into a scoped, sequenced project. We start with an honest gap assessment against the EU-GMP and GACP standards, then help you close the gaps in the order that matters. Our support spans EU-GMP certification readiness, GACP certification, mock EU-GMP inspections, contamination control strategy development, SOP and quality system build, Qualified Person facing documentation, and QAP services for your Canadian licence. A good place to pressure test your own documentation is our list of the 10 SOPs every licensed facility gets wrong. Whether you are defending a German supply agreement or entering the market for the first time, we help you get inspection ready with less guesswork and less wasted time.

The most useful first step is a conversation about your specific facility, so you know what certification will take in weeks and in dollars before you commit to it.

Conclusion

Germany is not lost to Canada, but it is no longer guaranteed. The market is growing faster than Canada's share of it, and the reason certified competitors can take that share is that they cleared the one barrier that still matters: European quality certification. EU-GMP, backed by GACP and enforced by Qualified Person batch release, is the moat. Producers who hold it keep their access. Producers who treat certification as a project for next year are quietly ceding the market to the ones who treated it as a priority this year. The decision is commercial, the deadline is set by your competitors, and the first move is a clear eyed look at how far your site really is from the standard.

Sources and references

• BfArM, Federal Opium Agency, medicinal cannabis import and export statistics (in German)
• European Commission, EudraLex Volume 4, EU GMP guidelines including Annex 16
• EUR-Lex, Directive 2001/83/EC, Article 48 (the Qualified Person)
• Health Canada, importing and exporting cannabis for medical or scientific purposes